Medication Adherence

Whether and why patients take their medications as prescribed, for as long as prescribed, and the factors that encourage greater compliance with drug regimens.

The Association Between Analgesic Treatment Beliefs and Electronically Monitored Adherence for Cancer Pain

Salima Meghani, RN, PhD, Penn Nursing School researcher
Jan. 4, 2021

William E. Rosa, Barbara RiegelConnie M. Ulrich, Jesse Chittams, Ryan Quinn, Salimah H. Meghani

Abstract [from journal]

Objectives: To determine whether clusters based on analgesic treatment beliefs among patients with cancer predict objective analgesic adherence.

Sample & setting: 207 patients with cancer in the outpatient setting who were aged 18 years or older, self-identified as White or African American, were diagnosed with solid tumor or multiple myeloma, and were prescribed at least one around-the-clock analgesic prescription for reported cancer pain.

Methods & variables: 


Does Hospitalization For Thromboembolism Improve Oral Anticoagulant Adherence In Patients With Atrial Fibrillation?

Allison Willis, MD
Aug. 31, 2020

Thanh Phuong Pham Nguyen, Yong Chen, Dylan Thibault, Charles E. Leonard, Sean Hennessy, Allison Willis

Abstract [from journal]

Background: It is not known how medication adherence changes after hospitalization for a sentinel thromboembolic event.

Objective: The purpose of this study was to examine the impact of hospitalization for ischemic stroke or thromboembolism on postdischarge adherence to oral anticoagulants in patients with atrial fibrillation.

Methods: We conducted a quasi-experimental pre-post observational study using a large U.S. commercial insurance health care claims database.


Olaparib And Durvalumab In Patients With Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An Open-Label, Multicentre, Phase 1/2, Basket Study

Aug. 6, 2020

Susan M. Domchek, Sophie Postel-Vinay, Seock-Ah Im, Yeon Hee Park, Jean-Pierre Delord, Antoine Italiano, Jerome Alexandre, Benoit You, Sara Bastian, Matthew G. Krebs, Ding Wang, Saiama N. Waqar, Mark Lanasa, Joon Rhee, Haiyan Gao, Vidalba Rocher-Ros, Emma V. Jones, Sakshi Gulati...

Abstract [from journal]

Background: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in patients with germline BRCA1-mutated or BRCA2-mutated metastatic breast cancer.

Methods: The MEDIOLA trial is a multicentre, open-label, phase 1/2, basket trial of durvalumab and olaparib in solid tumours. Patients were enrolled into four initial


Nature Prescriptions For Health: A Review Of Evidence And Research Opportunities

Jun. 12, 2020

Michelle C. Kondo, Kehinde O. Oyekanmi, Allison Gibson, Eugenia C. South, Jason Bocarro, J Aaron Hipp

Abstract [from journal]

Nature prescription programs have emerged to address the high burden of chronic disease and increasingly sedentary and screen-based lifestyles. This study examines the base of evidence regarding such programs. We conducted a narrative review of published literature using four electronic databases. We included case studies, research design articles, and empirical studies that discussed any type of outdoor exposure or activities initiated by a health-care provider from an outpatient clinic. We examined articles for information on target


Preadmission Cannabis Use Is Positively Correlated With Inpatient Opioid Dose Exposure In Hospitalized Patients With Inflammatory Bowel Diseases

Shivan J. Mehta, MD, MBA
May. 22, 2020

Rahul S Dalal, Sonali Palchaudhuri, Christopher K Snider, James D Lewis, Shivan J Mehta, Gary R Lichtenstein


Background: Opioid use is associated with excess mortality in patients with inflammatory bowel disease (IBD). Recent data have highlighted that inpatient opioid exposure is associated with postdischarge opioid use in this population. It is unknown if preadmission use of cannabis, which is commonly used for symptom relief among patients with IBD, increases the risk for inpatient opioid exposure when patients lack access to cannabis for symptom management. We sought to determine the association between preadmission


Incidence Of Treatment For Opioid Use Disorder Following Nonfatal Overdose In Commercially Insured Patients

May. 1, 2020

Austin S. Kilaru, Aria Xiong, Margaret LowensteinZachary F. MeiselJeanmarie PerroneUtsha KhatriNandita MitraM. Kit Delgado

Abstract [from journal]

Importance: Timely initiation and referral to treatment for patients with opioid use disorder seen in the emergency department is associated with reduced mortality. It is not known how often commercially insured adults obtain follow-up treatment after nonfatal opioid overdose.

Objective: To investigate the incidence of follow-up treatment following emergency department discharge after nonfatal opioid overdose and patient characteristics associated with receipt of follow-up treatment.


Frequency of and Risk Factors for Potentially Inappropriate Medication Use in Parkinson's Disease

Allison Willis, MD
Apr. 7, 2020

Danielle S. Abraham, Thanh Phuong Pham Nguyen, Sean Hennessy, Daniel Weintraub, Shelly L. Gray, Dawei Xie, Allison W. Willis

Abstract [from journal]

Background: impairments in neurotransmitter pathways put Parkinson's disease (PD) patients at risk for drug-disease interactions and adverse medication events.

Objective: to determine the prevalence and risk factors for potentially inappropriate medication (PIM) prescriptions, as defined by the 2015 Beers List, in PD.

Methods: cross-sectional analysis was conducted on 2014 Medicare beneficiaries with PD who had parts A, B and D coverage. The prevalence of PIM prescriptions for older


Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial

Mar. 4, 2020

Alexander C. Fanaroff, Eric D. Peterson, Lisa A. Kaltenbach, Christopher P. Cannon, Niteesh K. Choudhry, Timothy D. Henry, Kevin J. Anstrom, David J. Cohen, Eileen Fonseca, Naeem D. Khan, Gregg C. Fonarow, Tracy Y. Wang

Abstract [from journal]

Importance: Pharmacy fill data are increasingly accessible to clinicians and researchers to evaluate longitudinal medication persistence beyond patient self-report.

Objective: To assess the agreement and accuracy of patient-reported and pharmacy fill-based medication persistence.

Design, Setting, and Participants: This post hoc analysis of the cluster randomized clinical trial ARTEMIS (Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study)


The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies

Aug. 16, 2019

Peter P ReeseKevin G VolppLouise B Russell, George Loewenstein, Jiali Yan, David Pagnotti, Ryan McGilloway, Troyen Brennen, Darra Finnerty, Karen Hoffer, Sakshum Chadha, Iwan Barankay

Abstract [from journal]

Background: Low adherence to statin (HMG-CoA reductase inhibitors) medication is common. Here, we report on the design and implementation of the Habit Formation trial. This clinical trial assessed whether the interventions, based on principles from behavioral economics, might improve statin adherence and lipid control in at-risk populations. We describe the rationale and methods for the trial, recruitment, conduct and follow-up. We also report on several barriers we encountered


Electronic Pill Bottles or Bidirectional Text Messaging to Improve Hypertension Medication Adherence (Way 2 Text): a Randomized Clinical Trial

Shivan J. Mehta, MD, MBA
Aug. 8, 2019

Shivan J. Mehta, Kevin G. Volpp, Andrea B. Troxel, Susan C. Day, Raymond Lim, Noora Marcus, Laurie Norton, Sophia Anderson, David A. Asch

Abstract [from journal]

Background: Poor medication adherence contributes to inadequate control of hypertension. However, the value of adherence monitoring is unknown.

Objective: To evaluate the impact of monitoring adherence with electronic pill bottles or bidirectional text messaging on improving hypertension control.

Design: Three-arm pragmatic randomized controlled trial.

Patients: One hundred forty-nine primary care patients aged 18-75 with hypertension and text messaging capabilities who